The strong revenue growth, margin expansion, and raised guidance suggest continued market penetration of MACI. Traders should monitor the commercial manufacturing ramp-up in the new Burlington facility and progress on the UK MHRA application as potential future catalysts.
Price Chart
Executive Summary
Vericel Corp reported strong Q4 and full-year 2025 financial results with total revenue of $276.3 million, driven by 21% growth in MACI revenue. The company achieved a 59% increase in net income to $16.5 million and raised its 2026 revenue guidance to $316-$326 million, signaling continued momentum in its advanced therapies business.
Key Financial Metrics
Key Facts
- Q4 2025 revenue grew 23% YoY to $92.9 million
- Full-year 2025 revenue reached $276.3 million, up 16% from 2024
- MACI revenue grew 21% to $239.5 million for the year
- Net income increased 59% to $16.5 million for the year
- 2026 revenue guidance raised to $316-$326 million
- Record Q4 gross margin of 79% and adjusted EBITDA margin of 40%
Financial Impact
Revenue growth of 16% and net income growth of 59% in 2025 with 2026 revenue guidance suggesting 14-18% growth
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| MACI | $239.5M | +21.0% |
| Burn Care | $36.8M | — |
Risk Factors
- Increased operating expenses due to new facility costs could pressure margins
- Dependence on MACI revenue growth (87% of total revenue)
- Regulatory risks with UK MHRA application
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-012003 |
| Document: vcel-20260226.htm | 0001628280-26-012003 |
| Document: 0001628280-26-012003-index-headers.html | 0001628280-26-012003 |
| Document: 0001628280-26-012003-index.html | 0001628280-26-012003 |
| Document: 0001628280-26-012003.txt | 0001628280-26-012003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | Insider Cluster | $45.36 $40.89 | ▼ −9.85% | ▼ −9.25% | $40.15 (−11.49%) |
Jul 30, 2026 9w ago | 8-K | $47.61 $41.18 | ▼ −13.51% | ▼ −17.47% | $40.15 (−15.67%) |
Jul 16, 2026 11w ago | Press Release | $47.81 $44.54 | ▼ −6.84% | ▼ −10.46% | $40.15 (−16.02%) |
Jun 30, 2026 13w ago | Insider Cluster | $45.15 $46.62 | ▲ +3.26% | ▲ +5.44% | $40.15 (−11.07%) |
Jun 2, 2026 17w ago | 144 | $34.45 $45.15 | ▲ +31.06% | ▲ +32.62% | $40.15 (+16.55%) |
May 15, 2026 20w ago | Insider Cluster | $34.87 $38.46 | ▲ +10.30% | ▲ +8.71% | $40.15 (+15.14%) |
May 7, 2026 21w ago | 8-K | $35.13 $34.74 | ▼ −1.11% | ▼ −4.25% | $40.15 (+14.29%) |
May 7, 2026 21w ago | Press Release | $35.13 $34.74 | ▼ −1.11% | ▼ −4.25% | $40.15 (+14.29%) |
Apr 23, 2026 23w ago | Press Release | $34.40 $35.40 | ▲ +2.91% | ▼ −1.73% | $40.15 (+16.72%) |
Mar 19, 2026 28w ago | DEFA14A | $32.74 $35.68 | ▲ +8.98% | ▲ +1.36% | $40.15 (+22.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access